Zevra TherapeuticsZVRA
ZVRA
About: Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Employees: 59
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
634% more call options, than puts
Call options by funds: $3.95M | Put options by funds: $539K
141% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 17
41% more capital invested
Capital invested by funds: $201M [Q3] → $283M (+$81.6M) [Q4]
33% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]
8.46% more ownership
Funds ownership: 55.04% [Q3] → 63.49% (+8.46%) [Q4]
9% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 23
0% more funds holding
Funds holding: 108 [Q3] → 108 (+0) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$18
150%
upside
Avg. target
$22
206%
upside
High target
$25
247%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Canaccord Genuity Sumant Kulkarni 10% 1-year accuracy 3 / 30 met price target | 247%upside $25 | Buy Maintained | 13 Mar 2025 |
Guggenheim Eddie Hickman 22% 1-year accuracy 2 / 9 met price target | 206%upside $22 | Buy Maintained | 13 Mar 2025 |
HC Wainwright & Co. Oren Livnat 53% 1-year accuracy 26 / 49 met price target | 178%upside $20 | Buy Reiterated | 13 Mar 2025 |
Citizens Capital Markets Jason Butler 28% 1-year accuracy 11 / 40 met price target | 150%upside $18 | Market Outperform Maintained | 12 Mar 2025 |
Cantor Fitzgerald Kristen Kluska 25% 1-year accuracy 25 / 101 met price target | 247%upside $25 | Overweight Reiterated | 12 Mar 2025 |
Financial journalist opinion
Based on 3 articles about ZVRA published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism
CELEBRATION, Fla., April 17, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announces the publication of “Mechanistic insights into arimoclomol mediated effects on lysosomal function in Niemann-pick type C disease” in Molecular Genetics and Metabolism.
Neutral
GlobeNewsWire
3 weeks ago
Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
CELEBRATION, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $150 million.
Neutral
GlobeNewsWire
4 weeks ago
Zevra Therapeutics Files Preliminary Proxy
Confirms Receipt of Two Director Nominees from Daniel J. Mangless Stockholders Are Not Required to Take Action at This Time CELEBRATION, Fla.
Neutral
Seeking Alpha
1 month ago
Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Nichol Ochsner - VP, IR and Corporate Communications Neil McFarlane - President and CEO LaDuane Clifton - CFO Joshua Schafer - Chief Commercial Officer and EVP, Business Development Adrian Quartel - Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Jason Butler - Citizens JMP Sumant Kulkarni - Canaccord Oren Livnat - H.C. Wainwright Samantha Corwin - William Blair Eddie Hickman - Guggenheim Securities Operator Good afternoon, and thank you for joining Zevra's Therapeutics Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Conference Call.
Neutral
Zacks Investment Research
1 month ago
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.40 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Zevra Reports Full Year 2024 and Fourth Quarter Financial Results
FY 2024 net revenue of $23.6 million, driven by net revenue of $12.0 million during fourth quarter of 2024 Entered into asset purchase agreement for sale of PRV for $150 million Company to host conference call and webcast today, Mar. 11, 2025, at 4:30 p.m. ET CELEBRATION, Fla.
Neutral
GlobeNewsWire
1 month ago
Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C
New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C
Neutral
GlobeNewsWire
1 month ago
Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
CELEBRATION, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $150 million upon the closing of the transaction, which is expected to take place within 30 to 45 days, subject to customary closing conditions.
Neutral
GlobeNewsWire
2 months ago
Zevra to Report 2024 Fourth Quarter and Full Year Financial Results
Company will host conference call on Tuesday, Mar. 11, 2025, at 4:30 p.m. ET Company will host conference call on Tuesday, Mar. 11, 2025, at 4:30 p.m. ET
Neutral
GlobeNewsWire
2 months ago
Zevra to Participate at Upcoming Investor Conferences
CELEBRATION, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will participate at the following March events:
Charts implemented using Lightweight Charts™